Welcome to our dedicated page for Envveno Medical Corporation SEC filings (Ticker: NVNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The enVVeno Medical Corporation (NASDAQ: NVNO) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into enVVeno’s clinical-stage medical device business, which focuses on bioprosthetic venous valves for deep venous disease, including severe deep chronic venous insufficiency.
Investors can review Form 10-K and other periodic reports for information on enVVeno’s single-segment medical device development operations, risk factors, and discussion of its lead product candidates, VenoValve® and enVVe®. Form 10-Q and related filings provide interim updates on financial position, cash resources, and development activities.
Form 8-K current reports are particularly relevant for tracking material events such as the FDA’s not-approvable letter and unfavorable appeal decision regarding the VenoValve PMA application, the establishment of an at-the-market equity offering program, and shareholder voting results on matters like equity incentive plans and authorization for a reverse stock split. Proxy materials, including DEF 14A, describe annual meeting agendas, board composition, executive compensation proposals, and capital structure items submitted to stockholders.
Through Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points, explain complex regulatory language, and draw attention to items such as capital-raising arrangements, reverse stock split approvals, and other governance decisions. Real-time updates from EDGAR ensure that new NVNO filings, including any future Forms 4 reporting insider transactions, are added promptly, helping investors and researchers analyze enVVeno’s regulatory history and ongoing disclosure record more efficiently.
enVVeno Medical Corporation files its annual report detailing a major strategic pivot after its surgically implanted VenoValve received a not-approvable letter from the FDA in August 2025 and a subsequent appeal was denied. The company is now concentrating on the enVVe System, a first-in-class, non-surgical, transcatheter replacement venous valve for severe chronic venous insufficiency, and has completed pre-clinical testing while beginning FDA discussions for a pivotal trial expected to start in 2026. enVVeno highlights that it has no product revenue, has incurred significant losses since inception, and may never achieve profitability without successful regulatory approval and commercialization of enVVe or future devices. The filing emphasizes substantial clinical, regulatory, manufacturing, reimbursement and financing risks, reliance on a small supplier base for porcine tissue and components, and the need for additional capital to continue development. As of June 30, 2025, non-affiliate common equity market value was $76.1 million, and as of March 24, 2026, there were 655,521 shares of common stock outstanding and 33 full-time employees.
Northstrive Fund II LP and Braeden Lichti filed a Schedule 13D on enVVeno Medical Corp after accumulating a 5.05% stake in its common stock. As of February 10, 2026, Lichti beneficially owned 33,151 shares, based on 655,606 shares outstanding as of January 20, 2026.
The investors sent a letter to enVVeno’s board recommending an immediate halt to all clinical operations and a formal strategic review. Their suggestions include returning capital to shareholders or pursuing a merger or reverse merger to preserve cash and limit further dilution, while reserving the right to increase or reduce their position.
Northstrive Fund II LP and Braeden Lichti have filed a Schedule 13D on enVVeno Medical Corp, shifting from a passive to an active investor stance. They report beneficial ownership of 33,151 common shares, representing 5.05% of enVVeno’s outstanding stock as of January 20, 2026.
The investors sent a letter to the company’s board on February 20, 2026 urging the board to immediately halt all clinical operations and begin a formal strategic review. Their recommendations include considering returning capital to shareholders or pursuing a merger or reverse merger to maximize shareholder value while preserving cash and limiting further dilution.
Perceptive Advisors LLC and related investors filed an amended ownership report showing beneficial ownership of 2,048,515 shares of enVVeno Medical Corporation common stock, representing 9.99% of the company. The stake is held through Perceptive Life Sciences Master Fund, which owns common shares and warrants.
The Master Fund directly holds 1,759,035 shares plus 861,192 warrants exercisable at $8.334 per share, but a 9.99% beneficial ownership limitation currently allows exercise of only 289,480 warrants. Perceptive Advisors is the investment manager and Joseph Edelman is its managing member.
Braeden Lichti and Northstrive Fund II LP have disclosed significant ownership stakes in enVVeno Medical Corp. Lichti reports beneficial ownership of 33,151 shares of common stock, representing 5.05% of the company, while Northstrive Fund II LP reports 20,129 shares, or 3.07%.
The percentages are based on 655,606 shares of enVVeno Medical Corp common stock issued and outstanding as of January 20, 2026, as reported by the company. Lichti, a Canadian citizen, is the manager of Northstrive Fund II LP, a Delaware entity, and holds both sole and shared voting and dispositive power over different portions of the shares.
enVVeno Medical Corporation received a Schedule 13G filing showing that investor Braeden Lichti beneficially owns 33,151 shares of common stock, representing 5.05% of the company. This total includes 13,022 shares over which he has sole voting and dispositive power.
Lichti also shares voting and dispositive power over 20,129 shares held through Northstrive Fund II LP, which separately reports beneficial ownership of those 20,129 shares, or 3.07% of the common stock. Percentages are based on 655,606 shares outstanding as of January 20, 2026.
enVVeno Medical Corporation reported that as of December 31, 2025, it held a cash and investments balance of approximately $28 million, highlighting its available liquidity at year end. The company also announced that it has regained compliance with the minimum bid price requirement and all other criteria for continued listing on The NASDAQ Stock Market, removing an immediate risk to its exchange listing. The announcement was made through a press release furnished as an exhibit to this report.
enVVeno Medical Corporation implemented a one-for-thirty-five reverse stock split of its common stock, effective January 20, 2026. Every 35 previously issued and outstanding shares were automatically combined into one share, with no change to the par value.
No fractional shares were issued; any fractional positions were rounded up to the nearest whole share. The number of common shares outstanding decreased from 22,946,223 to 655,606, while authorized common shares remain at 250,000,000.
The company proportionally adjusted outstanding stock options and warrants so that share amounts decreased by a factor of 35 and exercise prices increased by a factor of 35, preserving their overall economic value. The stock now trades on a reverse split-adjusted basis on Nasdaq under the symbol NVNO.
enVVeno Medical Corp’s chief executive officer and director, Robert A. Berman, reported insider transactions involving both common stock and equity awards. The Form 4 discloses a disposition of 22,236 shares of common stock, and a related filing shows changes in his derivative holdings.
In addition, 200,000 restricted stock units that were granted to him on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan were voluntarily surrendered and cancelled on December 16, 2025. These units were subject to vesting based on specified performance milestones, which were not achieved, so the unvested awards were given up and no longer provide rights to common shares.